Recent Updates
Recently added Catalysts
AQST Negative Sentiment Score: 25/100

AQUESTIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Aquestive Therapeutics, Inc. on Behalf of Aquestive Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is investigating Aquestive Therapeutics, Inc. on behalf of its stockholders due to potential violations of federal securities laws. This follows a notice from the FDA regarding deficiencies in Aquestive's New Drug Application for its drug candidate, Anaphylm, which is intended for treating severe allergic reactions. The communication from the FDA has led to a decline in the company's stock price. Investors who have suffered losses are encouraged to reach out for legal options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Aquestive received a notice from the FDA identifying deficiencies in its New Drug Application for Anaphylm.
  • The FDA's notice precludes discussion of labeling and post-marketing commitments for Anaphylm.
  • The stock price of Aquestive dropped following the recent FDA communication.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aquestive (AQST) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Aquestive stock and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ:AQST) on behalf of Aquestive stockholders. Our investigation concerns whether Aquestive has violated the federal securities laws and/or engaged in other unlawful business practices.
Investigation Details:
On January 9, 2026, Aquestive disclosed that it received a notice from the FDA that it “had identified deficiencies in the New Drug Application (NDA) submitted by the Company for its product candidate, Anaphylm™ (epinephrine) Sublingual Film, for the treatment of severe allergic reactions, including anaphylaxis, that preclude discussion of labeling and post-marketing commitments for Anaphylm.” Following this news, the price of the Company’s stock dropped.
If you purchased or otherwise acquired Aquestive shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities,
derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.

Tags

Aquestive Therapeutics
Bragar Eagel & Squire

Frequently Asked Questions

How can I contact Bragar Eagel & Squire about Aquestive?

You can call Brandon Walker or Melissa Fortunato at (212) 355-4648.

What triggered the investigation into Aquestive Therapeutics?

The FDA identified deficiencies in Aquestive's New Drug Application for Anaphylm.

What should I do if I lost money on Aquestive stock?

Contact Bragar Eagel & Squire to discuss your legal rights and options.

Is there a cost to discuss my case with Bragar Eagel & Squire?

There is no cost or obligation to discuss your claims with the firm.

Where is Bragar Eagel & Squire located?

The firm has offices in New York, South Carolina, and California.

Last updated: Jan 20, 2026